What labs should be ordered after each maintenance hemodialysis session?

Laboratory Testing After Maintenance Hemodialysis

For routine maintenance hemodialysis patients, order predialysis labs (not postdialysis) at monthly intervals, including: hemoglobin, BUN (for adequacy assessment via Kt/V or URR), serum electrolytes (sodium, potassium, calcium, phosphorus), and iron studies (ferritin and transferrin saturation) at least every 3 months.

Core Laboratory Panel

Dialysis Adequacy Assessment

• BUN (Blood Urea Nitrogen): Draw predialysis and postdialysis samples to calculate Kt/V or URR 1
  • Critical timing for postdialysis BUN: Use the "slow flow/stop pump" technique—reduce blood flow to 50-100 mL/min for 15 seconds, then draw from arterial port, OR stop pump completely and draw within 15-30 seconds 1
  • Drawing immediately at dialysis end (time 0) gives falsely low BUN due to access recirculation
  • Drawing 2-10 minutes post-reinfusion gives falsely high BUN due to urea rebound
  • The 15-30 second window provides the most accurate single-pool kinetic modeling

Anemia Management

• Hemoglobin: Measure predialysis only, preferably before the midweek session 2

  • Postdialysis hemoglobin increases 3-4 g/dL per liter of ultrafiltrate removed, making it unreliable 2
  • Predialysis values vary significantly between 2-day vs 3-day intervals; midweek is most representative

• Iron studies (every 3 months minimum): 3

  • Transferrin saturation (TSAT): Target ≥20%
  • Serum ferritin: Target ≥100 ng/mL
  • These should be monitored at least quarterly to optimize erythropoiesis and adjust IV iron dosing 3

Electrolytes and Mineral Metabolism

• Serum electrolytes: Sodium, potassium, calcium, phosphorus 1
• Magnesium: Part of routine monitoring
• These guide dialysate prescription adjustments and identify complications like hyperkalemia

Testing Frequency: The Evidence

Monthly testing is standard but may be excessive for stable patients. Recent high-quality research challenges traditional monthly protocols:

• A 2020 Canadian population study of 7,454 HD patients found no mortality benefit from monthly testing versus every 6 weeks (adjusted HR 1.16,95% CI 0.99-1.38), with no differences in cardiovascular events or hospitalizations 4

• A 2019 quality improvement study showed switching from 4-week to 6-week intervals maintained stable hemoglobin (60% at target) and phosphate control (46% at target) while saving $85 per patient-year 5

• A 2022 multicenter study found therapeutic interventions occurred only 5 times yearly for ESAs, 4 times for IV iron, and 1 time for phosphate binders despite monthly testing—suggesting reduced frequency is safe 6

However, guidelines still recommend monthly to quarterly intervals 1, 3, reflecting conservative practice standards despite emerging evidence.

Risk-Stratified Approach

Stable patients (at target hemoglobin, phosphorus, adequate Kt/V):

• Consider extending to every 6 weeks for routine parameters
• Maintain quarterly iron studies

High-risk patients requiring frequent interventions 6:

• Higher ferritin levels (suggesting ongoing inflammation)
• Frequent ESA dose changes
• Elevated PTH requiring alfacalcidol adjustments
• These patients benefit from monthly or more frequent monitoring

Additional Considerations

Residual Kidney Function

• If residual urea clearance (Kr) ≥2 mL/min, recheck quarterly and after any acute event 7
• Residual function significantly contributes to solute clearance and may allow reduced dialysis dose

Parameters NOT Needed Postdialysis

• Never draw postdialysis hemoglobin—it's artificially elevated and clinically meaningless 2
• Routine physical exams in asymptomatic patients rarely change management 8
• Bone x-rays showed no therapeutic utility in one study 8

Common Pitfalls to Avoid

1. Postdialysis BUN timing errors: Drawing too early (access recirculation) or too late (urea rebound) invalidates adequacy calculations 1

2. Ignoring predialysis timing: Drawing after dialysis initiation or from saline-filled needles gives falsely low predialysis BUN 1

3. Over-reliance on ferritin alone: In HD patients, ferritin is an acute-phase reactant and may be elevated despite functional iron deficiency; TSAT is more reliable 2

4. Excessive testing in stable patients: Monthly testing may represent medical over-testing without outcome benefit 4, 5

The key is balancing guideline-recommended surveillance with emerging evidence supporting personalized, risk-stratified monitoring intervals that maintain quality while reducing unnecessary testing.